Salix Pharmaceuticals, Ltd. Development Update; XIFAXAN(R) Trials Initiated In C. difficile-Associated Diarrhea, Irritable Bowel Syndrome And Hepatic Encephalopathy

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today reported that initial subjects have been enrolled and dosed in three late-stage trials designed to evaluate XIFAXAN(R) for the treatment of C. difficile-Associated Diarrhea (CDAD), Irritable Bowel Syndrome (IBS) and Hepatic Encephalopathy (HE). Additionally, initial subjects have been enrolled and dosed in a late-stage trial designed to evaluate an 1100 mg tablet formulation of COLAZAL(R) for the treatment of mildly to moderately active ulcerative colitis, and patient enrollment continues in two late-stage trials designed to evaluate granulated mesalamine for the maintenance of remission of ulcerative colitis. The Company intends to pursue label extensions for XIFAXAN for the indications noted above, as well as a formulation line extension for the new COLAZAL Tablet and an approval for granulated mesalamine.

Back to news